Press Releases MedinCell LIQUIDNET SYSTEMS

Equities

FR0004065605

Real-time Estimate Tradegate Other stock markets 02:30:59 17/05/2024 pm IST			5-day change	1st Jan Change
14.01 ^EUR	0.00%		0.00%	0.00%

15/05	Medincell: share price falls after disappointing clinical study	CF
14/05	Medincell Provides Update on Phase 3 mdc-CWM Clinical Trial	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Medincell Provides Update on Phase 3 mdc-CWM Clinical Trial	14/05	BU
Medincell to Host Videoconference on May 15, 2024, at 10:30 AM CEST to Discuss Company's Latest News, Outlook, and R&D Activities	13/05	BU
Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-749 as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia	09/05	AQ
Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia	08/05	BU
Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia	08/05	BU
Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia	08/05	BU
MedinCell S A : Inside Information / Other news releases	08/05	PU
Medincell announces the suspension of listing of its shares on Euronext Paris	08/05	BU
Medincell Enters Into Strategic Co-development and Licensing Agreement with AbbVie to Develop Next-generation Long-acting Injectable Therapies	16/04	BU
Medincell Enters Into Strategic Co-development and Licensing Agreement with AbbVie to Develop Next-generation Long-acting Injectable Therapies	16/04	BU
Unitaid Awards Medincell up to $6 million Extension Grant to Fight Malaria	08/04	BU
Unitaid Awards Medincell up to $6 million Extension Grant to Fight Malaria	08/04	BU
MedinCell to Present at the 23rd Annual Needham Virtual Healthcare Conference	27/03	BU
MedinCell to Present at the UBS Virtual CNS Day	15/03	BU
Pharmaceutical Industry Veteran Strategist Philippe Guy Becomes Chairman of MedinCell's Supervisory Board	13/03	BU
MedinCell's partner Teva Announces Recruitment Completion of Phase 3 Clinical Study of mdc-TJK Olanzapine Long-Acting Injectable	10/01	AQ
MedinCell, reporting of the Annual General Meeting	14/23/14	AQ
MedinCell S A : announces successful completion of patient enrollment in the Phase 3 study of F14 (mdc-CWM), a first-in-class therapy for localized pain relief after Total Knee Replacement	30/23/30	PU
MedinCell S A : > Text of resolutions	24/23/24	PU
MedinCell S A : > URD 2022-2023	24/23/24	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases MedinCell LIQUIDNET SYSTEMS

Equities

FR0004065605

Press Releases

Filters